Literature DB >> 22451461

Using ICD-9 codes to establish prevalence of malformations in newborn infants.

Lewis B Holmes1, Marie-Noel Westgate.   

Abstract

UNLABELLED: BACKGROUND The International Classification of Disease (ICD-9) codes are used to identify, after discharge, diagnoses from a review of the medical record and provide the basis for reimbursement. These codes have been used to establish the prevalence of malformations and to assess potential teratogens. We have analyzed the accuracy of codes 740 to 759.9 to identify newborn infants with malformations.
METHODS: The diagnoses and ICD-9 codes in the medical records of 1000 consecutive live-born and stillborn infants were compared to the information provided in the medical records of those infants.
RESULTS: One hundred twenty-seven of the 1000 infants had ICD-9 codes between 740 and 759.9. 67 (52.8%) of the codes identified minor features, such as birth marks and minor anomalies. Twenty-three (18.1%) of the codes designated a malformation and were correct. Two types of errors were identified in another 33 infants (26%) whose codes designated a malformation: either the pediatricians' notes described a less severe finding or the fact that there was no such abnormality. In addition, four malformed infants were missed in pregnancies that were either terminated electively or stillborn, as they did not have medical records.
CONCLUSION: The ICD-9 codes 740 to 759.9 identified accurately some infants (18%) with malformations, but identified incorrectly many others. The accuracy of the coding for identifying malformations would be improved if (1) the findings of the examining pediatricians were considered; (2) normal features of prematurity, such as patent foramen ovale and patent ductus arteriosus, were not considered malformations; (3) minor physical features were not assigned ICD-9 codes within the 740 to 759.9 sequence.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451461     DOI: 10.1002/bdra.23001

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  7 in total

1.  Modeling travel impedance to medical care for children with birth defects using Geographic Information Systems.

Authors:  Eric M Delmelle; Cynthia H Cassell; Coline Dony; Elizabeth Radcliff; Jean Paul Tanner; Csaba Siffel; Russell S Kirby
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-09-02

Review 2.  Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Authors:  Krista F Huybrechts; Brian T Bateman; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-10       Impact factor: 2.890

3.  The Impact of Technology on the Diagnosis of Congenital Malformations.

Authors:  Loreen Straub; Krista F Huybrechts; Brian T Bateman; Helen Mogun; Kathryn J Gray; Lewis B Holmes; Sonia Hernandez-Diaz
Journal:  Am J Epidemiol       Date:  2019-11-01       Impact factor: 4.897

4.  Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.

Authors:  Jessica Leung; Sheila C Dollard; Scott D Grosse; Winnie Chung; ThuyQuynh Do; Manisha Patel; Tatiana M Lanzieri
Journal:  Clin Ther       Date:  2018-02-04       Impact factor: 3.393

5.  Antidepressant use in pregnancy and the risk of cardiac defects.

Authors:  Krista F Huybrechts; Kristin Palmsten; Jerry Avorn; Lee S Cohen; Lewis B Holmes; Jessica M Franklin; Helen Mogun; Raisa Levin; Mary Kowal; Soko Setoguchi; Sonia Hernández-Díaz
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

Review 6.  Deciphering congenital anomalies for the next generation.

Authors:  Monica H Wojcik; Pankaj B Agrawal
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-10-07

7.  Disinfection By-Product Exposures and the Risk of Specific Cardiac Birth Defects.

Authors:  J Michael Wright; Amanda Evans; John A Kaufman; Zorimar Rivera-Núñez; Michael G Narotsky
Journal:  Environ Health Perspect       Date:  2016-08-12       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.